13 completed, 4 recruiting, 3 unknown, 1 not yet recruiting. 5 Not applicable, 5 Phase 3, 5 Phase 4, 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Completed 5 |
| Phase 3 | 5 | Completed 3, Recruiting 1, Terminated 1 |
| Phase 4 | 5 | Unknown 3, Completed 1, Not yet recruiting 1 |
| Phase 2 | 4 | Recruiting 3, Completed 1 |
| Phase 1 | 2 | Completed 2 |
Follow Reboxetine: new trials by email Literature Review of Reboxetine trials Research Report on Reboxetine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy of a Pharmacological Treatment (Reboxetine Plus Ritalin) Versus Dog-Assisted Therapy in PTSD methylphenidate (Ritalin®), Reboxetine, Placebo - PTSD, Posttraumatic Stress Disorder | Phase 2 | Recruiting | University of Haifa | 160 | 2026-08-01 | 2026-08-18 |
| Efficacy of Hydroxyzine for Patients With Panic Disorder Hydroxyzine, Escitalopram Oxalate - Panic Disorder | Phase 4 | Not yet recruiting | Sultan Qaboos University | 80 | 2023-12-30 | 2023-02-21 |
| Reboxetine for Sleep Apnoea After ENT Surgery Reboxetine 4 MG Oral Tablet, Placebo - Sleep Apnea, Obstructive | Phase 2 | Recruiting | Flinders University | 20 | 2023-08-10 | 2024-10-03 |
| The Role of the Brain in Mental and Physical Fatigue Reboxetine Pill, Methylphenidate Oral Product - Fatigue | Phase 3 | Recruiting | Vrije Universiteit Brussel | 62 | 2023-05-03 | 2025-06-18 |
| Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder Antidepressant - Major Depressive Disorder | Completed | Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital | 73336 | 2022-10-01 | 2023-08-18 | |
| Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD Methylphenidate, Reboxetine, Placebo - Posttraumatic Stress Disorder | Phase 2 | Recruiting | University of Haifa | 53 | 2022-06-01 | 2026-08-11 |
| A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE) AXS-12 (reboxetine), Placebo - Narcolepsy, Cataplexy | Phase 3 | Completed | Axsome Therapeutics, Inc. | 68 | 2021-10-20 | 2025-11-13 |
| A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy AXS-12 (reboxetine), Placebo - Narcolepsy, Cataplexy | Phase 3 | Completed | Axsome Therapeutics, Inc. | 90 | 2021-09-15 | 2026-05-28 |
| Studying the Role of Brain Molecules for Decision Making Methylphenidate, Reboxetine, Nicotine gum - Decision Making, Healthy | Not applicable | Completed | University of Zurich | 160 | 2020-12-17 | 2024-05-08 |
| Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects Citalopram 40mg, Reboxetine 8 mg, Placebo oral tablet - Stress Urinary Incontinence, Fecal Incontinence | Phase 1 | Completed | University Hospital Bispebjerg and Frederiksberg | 24 | 2019-09-17 | 2021-06-09 |
| The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making Methylphenidate, Reboxetine, Placebos - Healthy | Not applicable | Completed | University of Zurich | 120 | 2019-07-03 | 2020-05-01 |
| Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans Reboxetine, Rivastigmine, Placebo oral tablet - Healthy | Not applicable | Completed | University of Oxford | 107 | 2019-06-01 | 2020-06-16 |
| Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) AXS-12 (Reboxetine), Placebo - Narcolepsy, Cataplexy Narcolepsy | Phase 2 | Completed | Axsome Therapeutics, Inc. | 21 | 2019-04-05 | 2026-06-15 |
| Pharmacovigilance in Gerontopsychiatric Patients Phenobarbital, Phenytoin, Carbamazepine - Dementia, Depression | Phase 3 | Terminated | Hannover Medical School | 407 | 2015-01-01 | 2018-02-28 |
| Antidepressants and Bone Mineral Density sertraline, citalopram, venlafaxine - Bone Mineral Density Quantitative Trait Locus 7 | Phase 3 | Completed | Guiyang Medical University | 203 | 2012-03-01 | 2014-07-01 |
| Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK) MDMA, Reboxetine, 8 mg, Placebo - Mood Disorder, Substance-related Disorders | Phase 1 | Completed | University Hospital, Basel, Switzerland | 16 | 2009-04-01 | 2013-01-25 |
| Enhancement of Motor Function with Reboxetine and Transcranial Direct Current Stimulation reboxetine, Placebo, tDCS verum - Cerebral Stroke | Phase 4 | Completed | Universitätsklinikum Hamburg-Eppendorf | 12 | 2009-01-01 | 2024-12-10 |
| Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia Reboxetine, citalopram (SSRI) - Schizophrenia | Phase 4 | Unknown | Fundació Sant Joan de Déu | 249 | 2008-11-01 | 2011-02-21 |
| Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response. sertraline, triiodothyronine (T3), reboxetine - Major Depressive Disorder | Not applicable | Completed | Hadassah Medical Organization | 35 | 2007-09-01 | 2013-03-22 |
| Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder escitalopram, Reboxetine, No intervention - Major Depression, Pain | Phase 4 | Unknown | Hospital Universitari Vall d'Hebron Research Institute | 42 | 2005-09-01 | 2010-05-27 |
Showing 20 of 22. Sign in to see all of them.
Cataplexy (3) · Depression (3) · Depressive Disorder, Major (3) · Disorders of Excessive Somnolence (3) · Narcolepsy (3) · Schizophrenia (2) · Stress Disorders, Post-Traumatic (2) · Abdominal Pain (1) · Amphetamine-Related Disorders (1) · Anxiety Disorders (1) · Attention Deficit Disorder with Hyperactivity (1) · Dementia (1) · Emotional Regulation (1) · Fatigue (1) · Fecal Incontinence (1)
Axsome Therapeutics, Inc. (3) · University of Haifa (2) · University of Zurich (2) · Flinders University (1) · Fundació Sant Joan de Déu (1) · Geha Mental Health Center (1) · Guiyang Medical University (1) · Hadassah Medical Organization (1) · Hannover Medical School (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital (1) · Sultan Qaboos University (1) · University Hospital Bispebjerg and Frederiksberg (1) · University Hospital, Basel, Switzerland (1) · University of Oxford (1)
Israel (4) · Germany (3) · Switzerland (3) · United States (3) · Canada (2) · Denmark (2) · Spain (2) · Australia (1) · Belgium (1) · United Kingdom (1)
Avi Avital, PhD (2) · Philippe Tobler, PhD (2) · Batya Engel-Yeger, PhD (1) · Casas Miguel, Prof. (1) · Christian Gerloff, MD (1) · Danny J. Eckert, PhD (1) · Helge Frieling, Prof., MD (1) · Inbal Brenner, MD (1) · Jakob M. Koch, M.D. (1) · Jesper Sonne, DMSc (1) · Matthias E Liechti, MD (1) · Paz Toren (1) · Rena Cooper-Kazaz, MD (1) · Tsipi Milman, MD (1)
PMID 22700038, PMID 25004184, PMID 29912955, PMID 33175411, PMID 37639601, PMID 39076155, PMID 41601207, PMID 42608643
2005 (1), 2019 (1)